TuHURA Biosciences’ (HURA) “Market Outperform” Rating Reaffirmed at Citizens Jmp

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “market outperform” rating reissued by equities research analysts at Citizens Jmp in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $9.00 target price on the stock. Citizens Jmp’s price objective points to a potential upside of 294.74% from the stock’s current price.

A number of other research firms also recently commented on HURA. Citigroup initiated coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set an “outperform” rating on the stock. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Stock Down 7.7%

Shares of NASDAQ HURA opened at $2.28 on Tuesday. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.43. The firm’s 50-day simple moving average is $2.29 and its 200 day simple moving average is $2.02. The stock has a market cap of $145.19 million, a P/E ratio of -4.22 and a beta of -0.01.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. On average, sell-side analysts anticipate that TuHURA Biosciences will post -0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after acquiring an additional 35,426 shares in the last quarter. BlackRock Inc. bought a new position in shares of TuHURA Biosciences during the 2nd quarter valued at about $1,615,000. Geode Capital Management LLC boosted its position in shares of TuHURA Biosciences by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after purchasing an additional 39,710 shares in the last quarter. State Street Corp grew its stake in shares of TuHURA Biosciences by 4.9% in the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after purchasing an additional 13,594 shares during the last quarter. Finally, Apollon Wealth Management LLC grew its stake in shares of TuHURA Biosciences by 17.7% in the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock worth $283,000 after purchasing an additional 23,717 shares during the last quarter. 0.62% of the stock is owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.